One challenge for development of non toxic micro-CT contrast agents is to load a high concentration of an X-ray attenuating element in a nanoparticulate formulation with particle size distribution small enough to avoid accumulation in lungs but large enough to avoid kidney filtration. Binitio Biomedical’s Exia 160 and Exia 160XL meet these requirements with sufficient stealth properties for vascular imaging. In addition, they are made of components which are metabolized by catabolic pathways in the body thus enabling metabolic imaging of the myocardium and brown adipose tissue.
Medilumine is pleased to announce a new distribution partnership with NanoPET Pharma through its Viscover brand. Medilumine is now an authorized distributor of the full
Recent preclinical research by the laboratory of Dr. Hisataka Kobayashi (Director of Molecular Theranostics, NIH) explored the potential of carbonic anhydrase‑9 (CA9) as a theranostic
